Table 1. Patients’ characteristics and demographic data.

Characteristics	No (%) (n=189)
Age, median (range, yr)	64.03[32–87]
Sex
Male	64 (33.86)
Female	125 (66.14)
Baseline EGFR mutation status
19 del	99 (52.38)
21-L858R	84 (44.44)
Others	6 (3.18)
First-generation TKI
Icotinib	96 (50.79)
Gefitinib	90 (47.62)
Erlotinib	3 (1.59)
Baseline tumor staging
IIIB	1 (0.53)
IV	188 (99.47)
Disease progression modes
Gradual progression	78 (41.27)
Local progression	48 (25.40)
Dramatic progression	63 (33.33)

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.